MX2022011821A - Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar. - Google Patents

Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.

Info

Publication number
MX2022011821A
MX2022011821A MX2022011821A MX2022011821A MX2022011821A MX 2022011821 A MX2022011821 A MX 2022011821A MX 2022011821 A MX2022011821 A MX 2022011821A MX 2022011821 A MX2022011821 A MX 2022011821A MX 2022011821 A MX2022011821 A MX 2022011821A
Authority
MX
Mexico
Prior art keywords
lung inflammation
compositions
pulmonary edema
methods
treating pulmonary
Prior art date
Application number
MX2022011821A
Other languages
English (en)
Spanish (es)
Inventor
David H Ingbar
Timothy P Rich
Robert J Schumacher
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of MX2022011821A publication Critical patent/MX2022011821A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/12Pulmonary diseases
    • G01N2800/125Adult respiratory distress syndrome
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2022011821A 2020-03-27 2021-03-26 Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar. MX2022011821A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063000939P 2020-03-27 2020-03-27
PCT/US2021/024345 WO2021195488A1 (en) 2020-03-27 2021-03-26 Compositions and methods for treating pulmonary edema or lung inflammation

Publications (1)

Publication Number Publication Date
MX2022011821A true MX2022011821A (es) 2022-10-10

Family

ID=77892642

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011821A MX2022011821A (es) 2020-03-27 2021-03-26 Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.

Country Status (7)

Country Link
US (1) US12569459B2 (https=)
EP (1) EP4126104A4 (https=)
JP (1) JP2023520770A (https=)
CN (1) CN115551569A (https=)
CA (1) CA3177377A1 (https=)
MX (1) MX2022011821A (https=)
WO (1) WO2021195488A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025024778A1 (en) * 2023-07-27 2025-01-30 Regents Of The University Of Minnesota Medical treatment system and methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716877B2 (en) 2001-01-31 2004-04-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
CA2578709C (en) 2004-06-17 2010-06-15 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
US9220788B2 (en) * 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20090022806A1 (en) 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
US8309080B2 (en) 2007-12-06 2012-11-13 Naidu Lp Metallo-protein and tocotrienol (MP-T3) compositions and uses thereof
US8304401B2 (en) 2008-09-02 2012-11-06 Trustees Of Dartmouth College Compositions and methods for decreasing type III deiodinase activity to modulate adiposity and blood glucose levels
WO2010124372A1 (en) * 2009-04-29 2010-11-04 Genomedx Biosciences, Inc. Systems and methods for expression-based classification of thyroid tissue
PT2501413T (pt) 2009-11-18 2019-07-10 Nektar Therapeutics Formas de sal de ácido de conjugados de polímero-fármaco
EP3119768B1 (en) 2014-03-16 2019-07-31 Hadasit Medical Research Services And Development Ltd. 3,4-bromo or -sulfonate substituted 1h-pyrrole-2,5-dione derivatives as type iii deiodinase (dio3) inhibitors for treating depressions and cancer
US9913819B2 (en) 2014-06-12 2018-03-13 Yale University Methods of treating or preventing fibrotic lung diseases
CN107041879A (zh) 2017-04-01 2017-08-15 深圳市润佳通科技有限公司 甲状腺激素及其药学上可接受的盐或前药在制备治疗和/或预防肺部疾病的药物中的应用
MX2020007971A (es) 2018-01-31 2020-09-09 Univ Minnesota Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
WO2019178023A1 (en) 2018-03-12 2019-09-19 Yale University Methods of Treating or Preventing Acute Respiratory Distress Syndrome

Also Published As

Publication number Publication date
JP2023520770A (ja) 2023-05-19
EP4126104A4 (en) 2024-04-17
US20230147865A1 (en) 2023-05-11
EP4126104A1 (en) 2023-02-08
CA3177377A1 (en) 2021-09-30
CN115551569A (zh) 2022-12-30
US12569459B2 (en) 2026-03-10
WO2021195488A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MX2020007971A (es) Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
MY208749A (en) Biligand drug conjugates and uses thereof
NZ714963A (en) Compositions and methods for treating anemia
MX346244B (es) Composiciones de vancomicina en polvo seco y metodos asociados.
BR112022001344A2 (pt) Combinações de antibióticos beta-lactâmicos administrados por via oral e derivados de avibactam para tratamento de infecções bacterianas
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
EP4306523A3 (en) Imidazoquinoline compounds and uses thereof
EP4609912A3 (en) New use of a combination of sacubitril and valsartan
MX2024011142A (es) Tratamiento de neurofibromas cutaneos con mirdametinib.
EP4410295A3 (en) Use of vibegron to treat overactive bladder
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2022011821A (es) Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
MY193963A (en) Composition for treating joint diseases and kit containing same
WO2020128614A8 (en) Method for treating interstital lung disease
MX2025005154A (es) Formulaciones orales compactables de ibutamoren.
MX2025000142A (es) Tratamiento con ciclobenzaprina para las secuelas postagudas de la infección por (sars)-cov-2 (pasc)
MX384760B (es) Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
MX2022012693A (es) Composicion que comprende metilfolato.
MX2008011321A (es) Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual.
ZA202400915B (en) Pharmaceutical composition and use thereof
WO2023019095A3 (en) Momelotinib combination therapy
EP4321216A3 (en) Compositions and methods for treating inflammatory neurological disorders
WO2022177968A8 (en) Therapeutic methods
WO2023059716A8 (en) Compositions and methods for levodopa delivery